Evox Therapeutics to expand work on cell-targeted delivery of nucleic acid-based

Evox Therapeutics, a leading exosome therapeutics company, has announced that it has secured an undisclosed amount of funding from the Bill & Melinda Gates Foundation.

The funds will be used to support the company's development of cell-targeted exosome-based approaches to more effectively deliver a nucleic acid-based anti-infective drug.

Evox is engineering exosomes, the body’s natural vesicular delivery system, to enable a wide variety of drugs to reach previously inaccessible tissues and compartments, such as crossing the blood–brain barrier to deliver drugs to the central nervous system, intracellular delivery of biologics and extra-hepatic delivery of RNA therapeutics.

Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented: “We are pleased to be working with the Bill & Melinda Gates Foundation to maximise the effectiveness of their therapeutic drug through cell- and tissue-targeted exosome-mediated delivery."

"The foundation has a reputation for working with partners that can drive meaningful change – this funding is a testament to the quality of our platform and its potential application in areas of high medical need.”